{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:36:21Z","timestamp":1787164581591,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Eine schwere, nicht kontrollierte chronische Rhinosinusitis mit nasalen Polypen (CRSwNP) kann sich unter Dupilumab 300\u202fmg 2\u2011w\u00f6chentlich komplett zur\u00fcckbilden. Sp\u00e4testens dann folgt die Frage der Patienten nach einer m\u00f6glichen Therapiedeeskalation. Eine Beendigung der Antik\u00f6rpertherapie nach 24\u00a0Wochen f\u00fchrte zum Rezidiv, hingegen blieb unter reduzierter Dupilumab-Dosis durch Streckung des Intervalls auf 4\u00a0Wochen die Kontrolle erhalten. Eine vom Zulassungstext abweichende Verl\u00e4ngerung der Therapieintervalle wird jedoch aktuell nicht empfohlen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methoden<\/jats:title>\n                    <jats:p>Es erfolgte eine retrospektive Untersuchung des Verlaufs von 29\u00a0Patienten mit schwerer CRSwNP, mit Typ-2-Inflammation assoziierten Komorbidit\u00e4ten und bestehender Indikation zur Biologikatherapie. Nach R\u00fcckbildung der CRSwNP und der Beschwerden unter Dupilumab 300\u202fmg 2\u2011w\u00f6chentlich war das Applikationsintervall individuell zun\u00e4chst auf 4\u00a0Wochen, danach ggf. auf 6\u00a0Wochen verl\u00e4ngert worden. Erfasst wurden u.\u202fa. die Lebensqualit\u00e4t (Sinonasal Outcome Test, SNOT-22), der nasale Polypenscore (NPS) und das Riechverm\u00f6gen (Sniffin\u02bc Sticks, Fa.\u00a0Burghart Messtechnik, Holm, Deutschland).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Alle Patienten zeigten innerhalb der ersten 3\u00a0Monate ein sehr gutes Therapieansprechen. Eine Verl\u00e4ngerung des Dupilumab-Intervalls auf 4\u00a0Wochen erfolgte nach 7\u201331\u00a0Monaten (median 13\u00a0Monate), auf 6\u00a0Wochen (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u20099) nach 17\u201335\u00a0Monaten (median 23\u00a0Monate). Im Verlauf traten bei keinem Patienten ein Rezidiv, eine Verschlechterung der Lebensqualit\u00e4t oder des Riechens auf.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Eine Verl\u00e4ngerung der Dupilumab-Injektionsintervalle auf\u00a04 evtl. auch 6\u00a0Wochen ist individuell nach weitestgehender R\u00fcckbildung der Polypen und Beschwerden ohne klinische Verschlechterung m\u00f6glich. Weitere Studien zur Deeskalation bzw. Beendigung der Biologikatherapie bei erzielter CRSwNP-Kontrolle sind unabdingbar.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00106-024-01487-y","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T11:15:37Z","timestamp":1716030937000},"page":"499-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chronische Rhinosinusitis mit nasalen Polypen\u00a0\u2013 Verl\u00e4ngerung der Dupilumab-Therapieintervalle","Chronic rhinosinusitis with nasal polyps\u2014extension of dupilumab treatment intervals"],"prefix":"10.1007","volume":"72","author":[{"given":"H. M.","family":"Appel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lochbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. K.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"1487_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1","author":"C Bachert","year":"2019","unstructured":"Bachert\u00a0C et\u00a0al (2019) Efficay and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP 52): results from a\u00a0multicentre, randomized, double-blind, placebo-controlled, parallel-group phase\u00a03\u00a0trials. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"1","key":"1487_CR2","doi-asserted-by":"publisher","first-page":"P29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert\u00a0C et\u00a0al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J\u00a0Allergy Clin Immunol 147(1):P29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013 (Corrigenda 147; 5, P1981\u20131982, 2021; https:\/\/doi.org\/10.1016\/j.jaci.2021.02.011)","journal-title":"J Allergy Clin Immunol"},{"key":"1487_CR3","doi-asserted-by":"crossref","first-page":"p93","DOI":"10.1111\/all.13238","volume":"73","author":"G B\u00f6lke","year":"2018","unstructured":"B\u00f6lke\u00a0G, Church\u00a0MK, Bergmann\u00a0KC (2018) Extended dose intervals vs dose reduction of omalizumab for controlled allergic asthma. Allergy 73:p93 (abstract 0164)","journal-title":"Allergy"},{"key":"1487_CR4","doi-asserted-by":"publisher","first-page":"100703","DOI":"10.1016\/j.waojou.2022.100703","volume":"15","author":"G B\u00f6lke","year":"2022","unstructured":"B\u00f6lke\u00a0G et\u00a0al (2022) Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma. World Allergy Organ\u00a0J 15:100703","journal-title":"World Allergy Organ J"},{"issue":"3","key":"1487_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens\u00a0WJ et\u00a0al (2023) EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 61(3):194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinology"},{"key":"1487_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4193\/Rhin23.415","volume":"13","author":"WJ Fokkens","year":"2024","unstructured":"Fokkens\u00a0WJ et\u00a0al (2024) EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology 13:62. https:\/\/doi.org\/10.4193\/Rhin23.415","journal-title":"Rhinology"},{"key":"1487_CR7","unstructured":"G\u2011BA Off-Label-Use \u2013 Verordnungsf\u00e4higkeit von Arzneimitteln in nicht zugelassenen Anwendungsbieten. https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/off-label-use"},{"key":"1487_CR8","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/all.15650","volume":"78","author":"P Gevaert","year":"2023","unstructured":"Gevaert\u00a0P et\u00a0al (2023) European academy of allergy and clinical immunology position paper on endoscopic scoring of nasal polyposis. Allergy 78:912\u2013922","journal-title":"Allergy"},{"key":"1487_CR9","doi-asserted-by":"publisher","DOI":"10.1055\/a-1197-0136","author":"L Klimek","year":"2020","unstructured":"Klimek\u00a0L et\u00a0al (2020) Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem. Laryngo-Rhino-Otol. https:\/\/doi.org\/10.1055\/a-1197-0136","journal-title":"Laryngo-Rhino-Otol"},{"key":"1487_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1055\/a-1908-3074","volume":"101","author":"L Klimek","year":"2022","unstructured":"Klimek\u00a0L et\u00a0al (2022) Empfehlungen zur \u00dcberpr\u00fcfung der Wirksamkeit und Verlaufsdokumentation von Dupilumab bei chronischer Rhinosinusitis mit Nasenpolypen (CRSwNP) im deutschen Gesundheitssystem. Laryngo-Rhino-Otol 101:855\u2013865","journal-title":"Laryngo-Rhino-Otol"},{"issue":"11","key":"1487_CR11","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1111\/all.15439","volume":"77","author":"LS Spekhorst","year":"2022","unstructured":"Spekhorst\u00a0LS et\u00a0al (2022) Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy 77(11):3398\u20133407. https:\/\/doi.org\/10.1111\/all.15439","journal-title":"Allergy"},{"key":"1487_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/all.15796","volume":"00","author":"RJL Van der Lans","year":"2023","unstructured":"Van der Lans\u00a0RJL et\u00a0al (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6\u00a0months. Allergy 00:1\u201314. https:\/\/doi.org\/10.1111\/all.15796","journal-title":"Allergy"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-024-01487-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01487-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T08:03:15Z","timestamp":1718956995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-024-01487-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1487"],"URL":"https:\/\/doi.org\/10.1007\/s00106-024-01487-y","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"4 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.M.\u00a0Appel hat Honorare f\u00fcr Vortr\u00e4ge und Beratert\u00e4tigkeiten sowie Fortbildungsunterst\u00fctzungen von Allergopharma, Sanofi und GSK erhalten. R.\u00a0Lochbaum, T.K.\u00a0Hoffmann und J.\u00a0Hahn geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen wurden mit Zustimmung der zust\u00e4ndigen Ethik-Kommission der Universit\u00e4t Ulm (Antrag Nr. 321\/22), im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patienten liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}